Gilberto Lopes, Chief of the Division of Medical Oncology at the Sylvester Comprehensive Cancer Center, shared a post on X:
“And, as we are talking RET, The new kid on the block: LUNBOTINIB.
We have the trial open Sylvester Comprehensive Cancer Center in Miami.
Impressive ASCO26 data (Abstract 8505): lunbotinib, a next-gen brain-penetrant RET inhibitor, posts ORR 87% in PRE-TREATED RET+ NSCLC (mPFS 27.5 mo) and 81% treatment-naïve, with deep CNS activity – 6 complete intracranial responses per cohort. The pre-treated number outshining naïve is the surprise.”
FDA Approves FoundationOne CDx as Companion Diagnostic for TEPMETKO in METex14 NSCLC
